Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?

Group 1 - Aligos Therapeutics, Inc. (ALGS) is currently outperforming its peers in the Medical sector with a year-to-date performance of 17.1%, compared to the sector average of 10.3% [2] - The Zacks Consensus Estimate for ALGS' full-year earnings has increased by 55.3% over the past 90 days, indicating improving analyst sentiment and a positive earnings outlook [2] - Aligos Therapeutics, Inc. holds a Zacks Rank of 2 (Buy), suggesting a favorable investment opportunity [1][2] Group 2 - Aligos Therapeutics, Inc. is part of the Medical - Biomedical and Genetics industry, which ranks 83 in the Zacks Industry Rank, while this industry has shown an average gain of 0% year-to-date [3] - Clover Health Investments, Corp. (CLOV), another outperforming stock in the Medical sector, has seen a year-to-date increase of 163.6% and holds a Zacks Rank of 2 (Buy) [2][3] - The Medical Info Systems industry, to which Clover Health belongs, is currently ranked 74 and has experienced a decline of 12.9% year-to-date [3]